Double blind cross-over clinical trial of acebutolol and propranolol in angina pectoris. 1985

P Pandhi, and V Sethi, and B K Sharma, and P L Wahi, and P L Sharma

Twenty-four patients with classical angina of effort completed this double-blind cross-over clinical trial of acebutolol and propranolol. Both acebutolol (100-400 mg) and propranolol (40-160 mg) three times a day produced a significant reduction in the incidence of anginal attacks, consumption of nitroglycerine tablets and increased exercise tolerance. Both drugs produced mild and tolerable side effects which did not require any reduction of doses of the drugs being used. No change in laboratory parameters assessing the function of the liver, the kidneys and the hemopoietic system was found. The commonly accepted dose ratio of 1:2.5 propranolol and acebutolol, respectively, was found to be true in less than 50% of the patients. Therefore, for optimal effect, the dose of acebutolol should be individualized depending upon the response.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011433 Propranolol A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs. Dexpropranolol,AY-20694,Anaprilin,Anapriline,Avlocardyl,Betadren,Dociton,Inderal,Obsidan,Obzidan,Propanolol,Propranolol Hydrochloride,Rexigen,AY 20694,AY20694,Hydrochloride, Propranolol
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005082 Physical Exertion Expenditure of energy during PHYSICAL ACTIVITY. Intensity of exertion may be measured by rate of OXYGEN CONSUMPTION; HEAT produced, or HEART RATE. Perceived exertion, a psychological measure of exertion, is included. Physical Effort,Effort, Physical,Efforts, Physical,Exertion, Physical,Exertions, Physical,Physical Efforts,Physical Exertions
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000070 Acebutolol A cardioselective beta-1 adrenergic antagonist with little effect on the bronchial receptors. The drug has stabilizing and quinidine-like effects on cardiac rhythm, as well as weak inherent sympathomimetic action. Acebutolol Hydrochloride,Acetobutolol,Apo-Acebutolol,M & B 17803A,M&B-17803 A,Monitan,Neptal,Novo-Acebutolol,Prent,Rhotral,Sectral,Apo Acebutolol,ApoAcebutolol,M&B 17803 A,M&B17803 A,Novo Acebutolol,NovoAcebutolol

Related Publications

P Pandhi, and V Sethi, and B K Sharma, and P L Wahi, and P L Sharma
November 1972, The Journal of the Association of Physicians of India,
P Pandhi, and V Sethi, and B K Sharma, and P L Wahi, and P L Sharma
July 1971, American heart journal,
P Pandhi, and V Sethi, and B K Sharma, and P L Wahi, and P L Sharma
April 1965, British medical journal,
P Pandhi, and V Sethi, and B K Sharma, and P L Wahi, and P L Sharma
April 1985, International journal of clinical pharmacology, therapy, and toxicology,
P Pandhi, and V Sethi, and B K Sharma, and P L Wahi, and P L Sharma
July 1975, JPMA. The Journal of the Pakistan Medical Association,
P Pandhi, and V Sethi, and B K Sharma, and P L Wahi, and P L Sharma
June 1977, The Journal of the Association of Physicians of India,
P Pandhi, and V Sethi, and B K Sharma, and P L Wahi, and P L Sharma
October 1987, American heart journal,
P Pandhi, and V Sethi, and B K Sharma, and P L Wahi, and P L Sharma
July 1969, L'union medicale du Canada,
P Pandhi, and V Sethi, and B K Sharma, and P L Wahi, and P L Sharma
August 1963, British medical journal,
P Pandhi, and V Sethi, and B K Sharma, and P L Wahi, and P L Sharma
October 1974, Annals of clinical research,
Copied contents to your clipboard!